Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O00308
UPID:
WWP2_HUMAN
Alternative names:
Atrophin-1-interacting protein 2; HECT-type E3 ubiquitin transferase WWP2; WW domain-containing protein 2
Alternative UPACC:
O00308; A6NEP1; B2R706; B4DTL5; F5H213; H3BRF3; I3RSG8; Q6ZTQ5; Q96CZ2; Q9BWN6
Background:
NEDD4-like E3 ubiquitin-protein ligase WWP2, also known as Atrophin-1-interacting protein 2 and WW domain-containing protein 2, plays a crucial role in protein ubiquitination. It facilitates the transfer of ubiquitin to substrates, influencing their degradation or functional modification. WWP2 targets several proteins for ubiquitination, including POU5F1, EGR2, SLC11A2, and RPB1, affecting processes in embryonic stem cells, T-cells, and beyond.
Therapeutic significance:
Understanding the role of NEDD4-like E3 ubiquitin-protein ligase WWP2 could open doors to potential therapeutic strategies. Its involvement in the regulation of key proteins through ubiquitination highlights its potential as a target for modulating cellular processes in disease states.